Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

OBJECTIVE: We investigated the mechanistic and pharmacological properties of anifrolumab, a fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal antibody in development for SLE. METHODS: IFNAR1 surface expression and internalisation on human monocytes before...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lupus Sci Med
Hoofdauteurs: Riggs, Jeffrey M, Hanna, Richard N, Rajan, Bhargavi, Zerrouki, Kamelia, Karnell, Jodi L, Sagar, Divya, Vainshtein, Inna, Farmer, Erika, Rosenthal, Kimberly, Morehouse, Chris, de los Reyes, Melissa, Schifferli, Kevin, Liang, Meina, Sanjuan, Miguel A, Sims, Gary P, Kolbeck, Roland
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2018
Onderwerpen:
Clinical Trials and Drug Discovery
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890856/
https://ncbi.nlm.nih.gov/pubmed/29644082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2018-000261
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items